ZINZINO AB (PUBL): PRELIMINARY SALES REPORT MARCH 2020

Strong sales growth during March; Zinzino group revenue increased with a total of 33%, compared with the previous year.

The revenues in March for Zinzino’s sales markets increased by 30% to MSEK 75.7 (58.4) primarily due to strong growth in Central Europe. Faun Pharma’s external sales increased by 89% and amounted to MSEK 6.6 (3.5). Overall, the Group increased revenues by 33% to MSEK 82.3 (61.9) compared with the previous year.

The first quarter of 2020 became the strongest quarter in the company’s history; the Zinzino based revenue in January–March increased 43% to MSEK 227.1 (158.4) compared to the previous year. Total revenue increased by 45% to MSEK 244.2 (168.3).

Revenues were distributed as follows:

The sales figures are prepared according to IFRS. Adjustment for IFRS 15, income from customers has affected comparative figures.

For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com

Pictures for publication free of charge:
Marcus Tollbom +46 (0) 70 190 03 12, marcus.tollbom@zinzino.com

Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email: certifiedadviser@penser.se

Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 14:30 the 6th of April 2020.

    
Zinzino AB (publ.) is a global Direct Sales company that markets and sells test-based nutrition, skincare and life-style products. Zinzino owns the Norwegian company BioActive Foods AS and the research and production unit Faun Pharma AS. Zinzino is based in Gothenburg, with additional offices in Helsinki, Riga, Oslo, Florida and Adelaide. Zinzino is a public company and its shares are listed on Nasdaq First North.